Medical Records and Privacy

Publication
Article
OncologyONCOLOGY Vol 13 No 10
Volume 13
Issue 10

ASCO just stated its policy on the privacy of medical records, which is a hot issue in Congress, especially because the House and Senate are in the midst of a conference committee on a financial services modernization bill. Medical records

ASCO just stated its policy on the privacy of medical records, which is a hot issue in Congress, especially because the House and Senate are in the midst of a conference committee on a financial services modernization bill. Medical records comes up via an amendment to H.R. 10, the House bill. Rep. Greg Ganske, MD (R-Iowa) proposed the amendment, which says that health insurers—who could be part of a banking conglomerate (hence, the inclusion of this amendment)—can never disclose a person’s medical information to a third party without obtaining his or her explicit approval. But the Ganske amendment includes an exception for “legitimate business purposes.” ASCO states that “insurers should explicitly state in their policies the purposes for which demographic and clinical information will be used, as well as assure that patient-specific information will be available only to providers of care.” That statement seems to rule out use of patient information for “legitimate business purposes,” per Ganske. Julie Taylor, deputy director of policy at ASCO, says the organization has no position on the Ganske amendment.

The Senate bill (S.900) has no medical records privacy provision, and Sen. Phil Gramm (R-Texas), the banking chairman, says he has no intention of including one. But his counterpart, Rep. Jim Leach (R-Iowa), wants to keep some facsimile of the Ganske amendment in the final bill.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content